Status | Study |
Enrolling by invitation |
Study Name: A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease Condition: Jansky-Bielschowsky Disease Batten Disease Date: 2016-01-15 Interventions: Drug: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1) |
Active, not recruiting |
Study Name: A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease Condition: Jansky-Bielschowsky Disease Batten Disease Date: 2015-04-24 Interventions: Biological: BMN 190 300 mg ICV infusion administered every other week for up to 240 weeks |
Completed |
Study Name: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease Condition: Jansky-Bielschowsky Disease Batten Disease Date: 2013-07-19 Interventions: Biological: BMN 190 30-300 mg ICV infusion administered every other week for at least 48 weeks. |